Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Aarti Drugs Limited

NSE: AARTIDRUGSPharmaceuticals

Share price

₹414.00

-0.85% close of 8 Oct 2026

Market cap ₹3,767 CrP/E 19.5

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

63

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹3,767 Cr

P/E ratio

19.5

P/B ratio

2.4

ROCE

12.0%

ROE

13.4%

Dividend yield

0.5%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹524.6052-week low ₹319.75

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 10.5% over the past year, and 13.2% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales held steady, near 12.3% over the last four years.

Whether it grew faster than its sector

It grew 13.2% a year against a sector median of 13.1% — 0.1 percentage points faster.

Room to re-rate, or risk of de-rating

At 19.5× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 22.8×, the 26th percentile of its own range.

Whether growth justifies the valuation

Priced at 3.9 times its growth rate, on earnings growth of 5%.

Profit growthPrice per ₹1 profitPer 1% growth
Aarti Drugs Limited — this one5%/yr19.5×₹3.9
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7
Cipla10%/yr29.6×₹3.0

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 79 of 130 on returns, 53 of 127 on growth, 91 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 12% on capital, ahead of 39% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1061 crore of cash from the business, spent ₹892 crore on plant and equipment, and returned ₹186 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 121 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 63 days for its cash to waiting 76 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue up 19% but profit down 7%, with volumes growing just 3.5%

Announced 31 Jul 2026 · Consolidated · Audited

Revenue

₹703 Cr

Revenue vs last year

+19.0%

Revenue vs last quarter

-2.4%

Net profit

₹50 Cr

Profit vs last year

-7.2%

Profit vs last quarter

-8.9%

Net margin

7.1%

EPS

₹5.49

Earnings call transcript · 3 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹3,767 Cr
Prev close
₹414.00
52w High
₹534
52w Low
₹319
Enterprise value
₹4,346 Cr
Beta
0.8
Price CAGR 1y
-18.0%
Price CAGR 3y
-7.0%
Price CAGR 5y
-8.0%
Price CAGR 10y
10.0%

Ratios

Return on assets
6.9%
PEG ratio
3.9
P/E ratio
19.5
P/B ratio
2.4
EV / EBITDA
14.0
Industry P/E
38.0
ROCE
12.0%
ROCE 5y average
15.2%
ROE
13.4%
Debt / Equity
0.4
Interest coverage
6.9
Dividend yield
0.5%
ROE 3y average
13.0%
ROE last year
13.0%

Annual P&L

Annual revenue
₹2,565 Cr
Annual profit
₹195 Cr
Operating margin
12.0%
Net profit margin
7.6%
EBITDA margin
12.2%
Sales growth 3y
-1.9%
Sales growth 5y
3.5%
Profit growth 3y
5.0%
Profit growth 5y
-7.0%
EPS
₹21.4
Sales growth TTM
11.0%
Profit growth TTM
2.0%
Dividend payout
9.0%

Quarter P&L

Sales latest quarter
₹703 Cr
Profit latest quarter
₹50 Cr
YoY quarterly sales growth
19.0%
YoY quarterly profit growth
-7.4%
OPM latest quarter
14.0%

Balance Sheet

Book Value
₹170
Face Value
₹10.0
Total debt
₹577 Cr
Total cash
₹9 Cr
Borrowings
₹577 Cr
Reserves / Equity
16.0

Cash Flow

Operating cash flow
₹254 Cr
Free cash flow
₹80 Cr
FCF yield
1.2%
Net cash flow
₹3 Cr

Shareholding

Promoter holding
54.4%
FII holding
1.5%
DII holding
10.3%
Public holding
33.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Aarti Drugs417.5519.83,8140.4850.1-4.1702.819.012.0
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales661642606620555598557677591653602720703
Expenses577565536534490531495583516569547624605
Material Cost375357385335427469
Change in Inventories39-12-7.4130-10-63
Purchases of Stock-in-Trade232931233321
Employee Cost313133333237
Other Expenses115112127127142140
Operating Profit84767086656762937484559698
OPM %131212141211111413139.151314
Other Income1121111220011-1
Exceptional items (within Other Income)00000-2.09
Interest9889999998989
Depreciation13131314131414151516181818
Profit before tax64565264444651715160297069
Tax %2430292624242712-625-402128
Net Profit48403747333537635445415550
EPS in Rs5.174.313.995.153.623.844.066.895.914.964.446.055.50
Diluted EPS in Rs6.885.914.954.446.055.49

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,0971,1401,1951,2441,5611,8062,1552,4892,7162,5292,3872,5652,678
Expenses9259601,0051,0421,3501,5411,7142,1562,4072,2082,0972,2542,344
Material Cost1,4381,504
Change in Inventories19-0.37
Purchases of Stock-in-Trade84115
Employee Cost112129
Other Expenses446508
Operating Profit172180190202211266440333309321290312333
OPM %16161616141520131113121212
Other Income104166511241621
Exceptional items (within Other Income)00
Interest42484038443726243738393634
Depreciation31373840434950505051566771
Profit before tax10095116125131185369270224236212211229
Tax %23282934322424242627218
Net Profit7769828290141280205166172168195191
EPS in Rs7.977.098.578.739.521530221819182121
Diluted EPS in Rs1821
Dividend Payout %41243333856559

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
8%
5 years
4%
3 years
-2%
TTM
11%

Compounded profit growth

10 years
11%
5 years
-7%
3 years
5%
TTM
2%

Stock price CAGR

10 years
10%
5 years
-8%
3 years
-7%
1 year
-18%

Return on equity

10 years
18%
5 years
15%
3 years
13%
Last year
13%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital242424242423939393929191
Reserves2843333764325206298209441,1001,1901,2781,458
Borrowings448483480546507389351543609564615577
Other Liabilities248261311388405535502629620587591690
Minority Interest0.340.37
Total Liabilities1,0041,1021,1911,3891,4551,5761,7662,2082,4212,4322,5752,815
Fixed Assets4484935816026256446656906768118661,086
CWIP1634142833121977210261330214
Investments5512111213171919202227
Other Assets5345705847487859071,0641,4221,5161,3401,3561,488
Total Assets1,0041,1021,1911,3891,4551,5761,7662,2082,4212,4322,5752,815

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1051331757014325115570133359245254
Cash from Investing Activity-107-99-107-74-62-33-72-150-164-224-165-173
Cash from Financing Activity1-33-684-80-215-819217-136-82-77
Net Cash Flow-11-0012213-14-1-23
Free Cash Flow-23468-58021478-82-311336881

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days105106911101079994110116102115118
Inventory Days828610013286102117115101107114112
Days Payable83909412385104931039494100109
Cash Conversion Cycle1041039711910997118123123115129121
Working Capital Days141922334454776372747676
ROCE %1818171721342115151312

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters595757565655555555555554
FIIs2.332.102.562.952.502.282.252.262.682.151.571.52
DIIs5.325.265.997.357.838.779.709.949.90101010
Public343534343434333333333334
No. of Shareholders1,67,4461,70,4141,57,5471,50,2181,90,2811,76,0061,69,7611,60,2601,52,2521,48,3631,44,9461,43,476

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -18.6% (₹508.40 → ₹414.00)Brick size ₹15.49 (fixed)Bricks 23
₹500₹414Nov '25Mar '26Jul '26
Price moved up one brickPrice moved down one brickLast close ₹414.00 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

company capacity utilisation %

70.00pct

2026-06-30

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

exports as % of revenue

32.00pct

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

1,66,81,845inr

2026-03-31

volume growth %

3.50pct

2026-06-30

News

News and filings about Aarti Drugs Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Benzoyl chloride
  • Dicyandiamide
  • Dimethylamine / methylamines
  • Ethyl 3-cyclopropylamino-2-(2,4-dichloro-5-fluorobenzoyl)acrylate

Depends on the price of

  • fuel

Sells to

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE767A01016

Plants

  • Baddi Pinnacle formulation plant · Baddi, Himachal Pradesh
  • Sarigam manufacturing facilities · Sarigam, Valsad, Gujarat
  • Sayakha amines facility · Sayakha, Gujarat
  • Tarapur manufacturing facilities · Palghar / Tarapur MIDC, Maharashtra

News impact

Big market events that reach Aarti Drugs Limited, and how the effect spreads.

Who it hits first

  • PetroChina, China's state oil giant, cancelled October gasoline (petrol) and jet fuel shipments meant for export.
  • With less Chinese fuel reaching Asia, regional petrol and jet-fuel prices rise and refining profit (the gap between crude cost and fuel price) widens for Indian fuel-makers.
  • Reliance Industries, the oil-to-retail giant, and MRPL, the Mangalore refiner, can sell fuel at richer margins for now.

Who may gain

  • Reliance Industries and MRPL gain higher export and domestic fuel margins while Chinese supply stays off.
  • Other Asian refiners with spare capacity also fetch better prices for petrol and jet fuel.

Along the supply chain

Downstream

Downstream, airlines like IndiGo, parcel carriers like Blue Dart and cement makers like UltraTech pay more for jet fuel, diesel and furnace fuel, squeezing their profits.

Upstream

Upstream, crude suppliers see steady demand as Indian refiners run plants harder to fill the gap left by China.

Where demand moves

Business

Business demand shifts: Asian buyers turn to Indian refiners like Reliance and MRPL for October petrol and jet fuel, lifting their sales volumes and prices.

Capital

Capital rotates into refiner shares on margin hopes while pulling from fuel-hungry airlines, logistics and cement makers facing cost squeezes.

How it spreads across sectors

Chemicals

Chemical makers face dearer fuel and feedstock, raising factory costs.

Construction Materials

Cement makers like UltraTech and India Cements pay more to fire kilns, trimming profits.

Oil, Gas & Consumable Fuels

Refiners earn fatter margins as Asian fuel supplies tighten on China's halt.

Services

Truckers and couriers pass on higher diesel costs or absorb margin hits.

Commodity angle

Commodity

fuel

Move series

fuel

Note

Fuel prices are up 32% over 3 months as China and others curb exports; margin impact bps were null for all signaled names because cost weights were unavailable, so signals use qualitative fuel-cost exposure instead.

Shock

price

Unit

A pattern seen before

Cascade chain

  • China fuel exports halted → Asian gasoline and jet fuel supplies tighten → refining margins up
  • Higher fuel prices → airline, logistics and cement costs up → margins squeezed
  • Costlier fuel → chemicals, textiles and FMCG input costs up → demand softens

Pattern name

Crude Oil Cascade

Patterns

  • Crude Oil Cascade
  • China Cascade

Sectors queried

  • Cement
  • Chemicals
  • FMCG
  • Pharma
  • Power
  • Textiles

When it plays out

Immediate

In 1-7 days Asian fuel prices jump and refiner shares firm while airline and logistics shares soften.

Medium term

In 1-6 months margins normalise if China resumes exports or other countries add supply; prolonged curbs keep fuel users under pressure.

Short term

In 1-4 weeks Indian refiners lift exports and fuel buyers pay higher October bills.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

9 Feb 2026interim₹2
4 Feb 2025interim₹1
6 Feb 2024interim₹1
8 Feb 2023interim₹1
9 Feb 2022interim₹1
3 Nov 2020interim₹2.5
30 Sep 2020bonus₹0
17 Feb 2020interim₹2

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.